Boehringer Ingelheim has announced the enrolment of the first patient in RE-COVERY DVT/PE, a global observational study on the management of deep vein thrombosis (DVT) and pulmonary embolism (PE).
“Large pivotal randomised trials have revolutionised our strategies to manage and reduce the risk of DVT and PE. However, it remains uncertain how the results of these trials impact everyday clinical practice in the real world. We are launching RE-COVERY DVT/PE, an exciting new global prospective observational cohort study, to learn more about DVT and PE patient treatments and outcomes,” said Samuel Z Goldhaber, professor of medicine at Harvard Medical School, Section Head of Vascular Medicine at Brigham and Women’s Hospital, and Chair of the RE-COVERY DVT/PE Steering Committee.
Pradaxa was approved for the treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.
The overall Boehringer Ingelheim research programme for Pradaxa, which includes the RE-COVERY DVT/PE study, will involve more than 120,000 patients worldwide across cardiovascular-related therapy areas, including stroke risk reduction in atrial fibrillation. The aim of the research programme is to deepen the science behind effective clot prevention and provide everyday support for patient management.